JPMorgan Chase & Co. Has $7.13 Million Position in Selecta Biosciences Inc (SELB)
JPMorgan Chase & Co. increased its position in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 365,138 shares of the company’s stock after acquiring an additional 6,292 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.63% of Selecta Biosciences worth $7,131,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Selecta Biosciences by 175.5% during the second quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock worth $4,322,000 after acquiring an additional 138,646 shares during the last quarter. State Street Corp boosted its position in Selecta Biosciences by 118.5% during the second quarter. State Street Corp now owns 152,430 shares of the company’s stock worth $3,027,000 after acquiring an additional 82,665 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Selecta Biosciences by 13.5% during the third quarter. Candriam Luxembourg S.C.A. now owns 143,000 shares of the company’s stock worth $2,610,000 after acquiring an additional 17,000 shares during the last quarter. Wasatch Advisors Inc. boosted its position in Selecta Biosciences by 66.5% during the second quarter. Wasatch Advisors Inc. now owns 124,392 shares of the company’s stock worth $2,470,000 after acquiring an additional 49,690 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Selecta Biosciences by 206.5% during the second quarter. Northern Trust Corp now owns 120,993 shares of the company’s stock worth $2,403,000 after acquiring an additional 81,516 shares during the last quarter. Hedge funds and other institutional investors own 54.44% of the company’s stock.
In other Selecta Biosciences news, insider Earl Sands bought 7,500 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were acquired at an average price of $10.26 per share, with a total value of $76,950.00. Following the purchase, the insider now owns 7,500 shares in the company, valued at approximately $76,950. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Timothy A. Springer bought 57,598 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average cost of $9.27 per share, for a total transaction of $533,933.46. Following the purchase, the director now owns 461,349 shares in the company, valued at approximately $4,276,705.23. The disclosure for this purchase can be found here. In the last three months, insiders bought 90,098 shares of company stock worth $843,933. Insiders own 41.90% of the company’s stock.
Selecta Biosciences Inc (SELB) opened at $10.04 on Thursday. Selecta Biosciences Inc has a 1-year low of $8.70 and a 1-year high of $24.02. The company has a quick ratio of 9.48, a current ratio of 9.48 and a debt-to-equity ratio of 0.32. The firm has a market cap of $221.63 and a price-to-earnings ratio of -3.24.
A number of brokerages have weighed in on SELB. Zacks Investment Research upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Saturday, November 11th. UBS Group lowered shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 price target on shares of Selecta Biosciences in a report on Tuesday, November 7th. Finally, ValuEngine lowered shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $23.50.
TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Has $7.13 Million Position in Selecta Biosciences Inc (SELB)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2017/12/28/jpmorgan-chase-co-has-7-13-million-position-in-selecta-biosciences-inc-selb.html.
Selecta Biosciences Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.